22 Participants Needed

Radiosurgery for Spasticity

(SPASM Trial)

Recruiting at 3 trial locations
DW
WL
BM
UO
Overseen ByUchechi Okafor, BS
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: Ohio State University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 2 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new method to help individuals with spasticity, characterized by very tight muscles. The treatment, called stereotactic radiosurgery dorsal rhizotomy, uses precise radiation beams aimed at nerves in the back to relax the muscles. Participants will be randomly assigned to either a real treatment group or a "sham" group (a control group that does not receive the actual treatment) to determine the real treatment's effectiveness. Individuals with long-term spasticity unresponsive to medication might be suitable for this trial. After six months, those in the sham group can opt to receive the real treatment. As an unphased trial, this study provides a unique opportunity for patients to explore innovative treatment options that might not be available elsewhere.

Will I have to stop taking my current medications?

The trial protocol does not specify whether you need to stop taking your current medications. However, since the trial is for people whose spasticity is not helped by their current medications, you might be able to continue them. It's best to ask the trial organizers for more details.

What prior data suggests that stereotactic radiosurgery dorsal rhizotomy is safe for treating spasticity?

Research shows that stereotactic radiosurgery dorsal rhizotomy uses precise radiation beams to target specific nerves in the back, aiming to reduce muscle stiffness, or spasticity. Studies on similar treatments have shown they can effectively reduce spasticity.

While direct safety data for this exact procedure is unavailable, similar treatments like selective dorsal rhizotomy have managed spasticity in children and young adults. These treatments are generally well-tolerated, though they can have side effects, as with any medical procedure.

The current trial does not focus on testing the treatment's safety in a new phase, indicating that the safety of this type of treatment is already somewhat understood. However, participants should discuss any concerns with their healthcare provider to understand potential risks.12345

Why are researchers excited about this trial?

Researchers are excited about the potential of stereotactic radiosurgery dorsal rhizotomy for treating spasticity because it offers a non-invasive approach, unlike traditional surgical options like selective dorsal rhizotomy. This treatment uses precise radiation to target the nerves responsible for muscle overactivity, potentially reducing spasticity without the need for incisions or long recovery times. By focusing radiation on specific neural pathways, it aims to provide relief with minimal side effects, which could be a game-changer for patients seeking alternatives to surgery or invasive procedures.

What evidence suggests that stereotactic radiosurgery dorsal rhizotomy is effective for spasticity?

In this trial, participants will receive either stereotactic radiosurgery dorsal rhizotomy (SRS) or a sham treatment. Research shows that SRS uses precise radiation to target specific nerves, helping to reduce muscle tightness. This treatment builds on the well-known procedure called selective dorsal rhizotomy (SDR), which reduces muscle stiffness in conditions like cerebral palsy. Studies have shown that SDR effectively lowers muscle stiffness and improves movement in children and young adults. The radiosurgery version aims to achieve similar results with a less invasive approach. Overall, early findings suggest it could be a promising option for easing muscle stiffness.12456

Who Is on the Research Team?

JP

Joshua Palmer, MD

Principal Investigator

Ohio State University

Are You a Good Fit for This Trial?

This trial is for individuals over 16 years old with chronic spasticity from conditions like stroke, SCI, or cerebral palsy that doesn't improve with medication. If under 18, parental consent is needed. It's not for those who can't lie on their back for the procedure, if the target nerve isn't visible on scans, or if pregnant.

Inclusion Criteria

I am older than 16 and if under 18, my parents have agreed to sign the consent.
My severe muscle stiffness hasn't improved with medication.

Exclusion Criteria

I cannot lie on my back for treatments.
The nerve we need to see cannot be seen on a CT or MRI scan.
I am not pregnant or have confirmed I am not pregnant through a test.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either stereotactic radiosurgery dorsal rhizotomy or a sham treatment

1 day
1 visit (in-person)

Follow-up

Participants are monitored for changes in spasticity and quality of life

6 months
Multiple visits (in-person and virtual)

Crossover Treatment

Participants who received the sham treatment are eligible to receive the real treatment

1 day
1 visit (in-person)

Long-term Follow-up

Participants are monitored for long-term changes in spasticity-related quality of life

2 years

What Are the Treatments Tested in This Trial?

Interventions

  • Sham
  • Stereotactic Radiosurgery Dorsal Rhizotomy
Trial Overview The study tests a treatment called stereotactic radiosurgery dorsal rhizotomy which aims to reduce muscle stiffness by targeting nerves with radiation. Participants are randomly assigned to receive either this real treatment or a sham (fake) procedure to compare outcomes.
How Is the Trial Designed?
2Treatment groups
Active Control
Placebo Group
Group I: SRS TreatmentActive Control1 Intervention
Group II: Sham TreatmentPlacebo Group1 Intervention

Stereotactic Radiosurgery Dorsal Rhizotomy is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Stereotactic Radiosurgery Dorsal Rhizotomy for:
🇪🇺
Approved in European Union as Selective Dorsal Rhizotomy for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Ohio State University

Lead Sponsor

Trials
891
Recruited
2,659,000+

Centro Diagnostico Milano, Co-PI: Pantaleo Romanelli, MD

Collaborator

Trials
1
Recruited
20+

Varian Medical Systems

Industry Sponsor

Trials
63
Recruited
3,700+

Dow R. Wilson

Varian Medical Systems

Chief Executive Officer since 2012

MBA from Dartmouth's Amos Tuck School of Business, BA from Brigham Young University

Dr. Deepak Khuntia

Varian Medical Systems

Chief Medical Officer since 2020

MD from the University of Cambridge, PhD from the University of Leicester

Published Research Related to This Trial

Selective dorsal rhizotomy significantly alleviates spasticity in children with cerebral palsy, as evidenced by improved knee and hip ranges of motion that approached normal limits after 10 years.
The study, which involved 11 children with spastic diplegia and used quantitative gait analysis over a long-term follow-up, demonstrated lasting functional benefits in gait, although step length and velocity remained below normal levels after a decade.
Gait before and 10 years after rhizotomy in children with cerebral palsy spasticity.Subramanian, N., Vaughan, CL., Peter, JC., et al.[2022]
Two cases of spinal cord tethering were reported as a previously unrecognized complication following selective dorsal rhizotomy (SDR) performed below the conus medullaris in children with spastic diparetic cerebral palsy.
Both patients initially showed improvement in spasticity and gait after SDR, but later developed urinary incontinence, highlighting the need for careful monitoring for this rare complication post-surgery.
Spinal cord tethering after selective dorsal rhizotomy below the conus medullaris.Belanger, K., McKay, W., Oleszek, J., et al.[2022]
In a study of 140 children with cerebral palsy undergoing selective dorsal rhizotomy (SDR), obesity was identified as a significant predictor of complications, including prolonged wound healing and superficial surgical site infections, with a notable odds ratio of 24.4 for wound healing issues.
The study found that while SDR is generally safe across all Gross Motor Functional Classification System (GMFCS) levels, non-ambulatory children (GMFCS IV and V) were more likely to require extended epidural pain management, highlighting the need for careful monitoring in this group.
Predictors of postoperative complications after selective dorsal rhizotomy.Wach, J., Yildiz, ÖC., Sarikaya-Seiwert, S., et al.[2021]

Citations

Radiosurgery Treatment for Spasticity Associated With ...This treatment is called "stereotactic radiosurgery dorsal rhizotomy." It uses very accurate beams of radiation to target certain nerves in the back to help ...
Outcomes of selective dorsal rhizotomy in ambulatory ...Selective dorsal rhizotomy (SDR) is an irreversible neurosurgical procedure which reduces spasticity in the lower limbs of children and young ...
The Evolution of Selective Dorsal Rhizotomy for ...Selective dorsal rhizotomy is a key technique in the surgical management of spasticity in patients with cerebral palsy.
Radiosurgery for Spasticity (SPASM Trial)Research shows that Selective Dorsal Rhizotomy (SDR), a component of the treatment, effectively reduces spasticity (muscle stiffness) in children with cerebral ...
Selective Dorsal Rhizotomy for Cerebral PalsyThe study highlights motor improvements and a reduced need for spasticity treatments, emphasizing SDR's potential to enhance outcomes and ...
Stereotactic Dorsolateral Irradiation of Spinal Nerve RootsA novel treatment option was offered to provide relief from spasticity and pain: stereotactic image-guided irradiation delivered to the sensory root.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security